Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics
|出版商||CBR Pharma Insights||商品編碼||345736|
|出版日期||內容資訊||英文 78 Pages
|醫藥品產業的各種交易趨勢 (2010-2015年)、近幾年交易活動的詳細分析 Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics|
|出版日期: 2017年07月01日||內容資訊: 英文 78 Pages||
Pharmaceutical market is continuing to see global growth, whereas pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy. Companies are considering various strategies to overcome the current challenges, with deal making being foremost among these as a means of boosting revenues over a short period of time.
Agreements between companies for drug discovery, which allow them to share the risk of co-developing products, have become more common. Small companies that primarily carry out early-stage research, development and production activities are entering into agreements with key industry leaders to out-license the rights to their products, utilizing the strengths of the larger companies in terms of commercialization expertise, manufacturing, distribution and marketing capabilities and global presence.
Meanwhile, key players keen to secure novel and promising molecules are willing to co-operate with small players to in-license promising early-stage assets to expand their portfolios, reduce R&D risks and move ahead in the market. Also, therapies have historically been manufactured in a one-size-fits-all approach for chronic diseases, among other therapy areas. Recently, a more personalized approach is being chosen by pharmaceutical companies, which are increasing the development of targeted therapies even for rare diseases.
The report "Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics" analyzes the importance of deal making in the pharmaceutical and healthcare market. There were a total of 2,028 deals made in 2016, with an aggregate deal value of $189 billion. Deal activity has a very wide range of purposes, including helping pharma companies to enhance their research and regulatory approaches, and aiding portfolio expansion and diversification, geographic expansion, entry into niche markets, commercialization, and sales.
Specifically, this report provides the following -
An overview of recent deal activity from 2010 to May 2017 is provided. It covers -
Trends in products involved in deals, based on molecule type, stage of development and type of deal
Companies mentioned in this report: Pfizer, Merck, Bayer, Allergan, Valeant.